Literature DB >> 17962055

A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: advantages of pathway-based discovery.

Marc K Hellerstein1.   

Abstract

Contemporary drug discovery and development (DDD) is dominated by a molecular target-based paradigm. Molecular targets that are potentially important in disease are physically characterized; chemical entities that interact with these targets are identified by ex vivo high-throughput screening assays, and optimized lead compounds enter testing as drugs. Contrary to highly publicized claims, the ascendance of this approach has in fact resulted in the lowest rate of new drug approvals in a generation. The primary explanation for low rates of new drugs is attrition, or the failure of candidates identified by molecular target-based methods to advance successfully through the DDD process. In this essay, I advance the thesis that this failure was predictable, based on modern principles of metabolic control that have emerged and been applied most forcefully in the field of metabolic engineering. These principles, such as the robustness of flux distributions, address connectivity relationships in complex metabolic networks and make it unlikely a priori that modulating most molecular targets will have predictable, beneficial functional outcomes. These same principles also suggest, however, that unexpected therapeutic actions will be common for agents that have any effect (i.e., that complexity can be exploited therapeutically). A potential operational solution (pathway-based DDD), based on observability rather than predictability, is described, focusing on emergent properties of key metabolic pathways in vivo. Recent examples of pathway-based DDD are described. In summary, the molecular target-based DDD paradigm is built on a naïve and misleading model of biologic control and is not heuristically adequate for advancing the mission of modern therapeutics. New approaches that take account of and are built on principles described by metabolic engineers are needed for the next generation of DDD.

Entities:  

Mesh:

Year:  2007        PMID: 17962055     DOI: 10.1016/j.ymben.2007.09.003

Source DB:  PubMed          Journal:  Metab Eng        ISSN: 1096-7176            Impact factor:   9.783


  11 in total

Review 1.  The discovery of first-in-class drugs: origins and evolution.

Authors:  Jörg Eder; Richard Sedrani; Christian Wiesmann
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

Review 2.  Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery.

Authors:  Maykel Cruz-Monteagudo; Stephan Schürer; Eduardo Tejera; Yunierkis Pérez-Castillo; José L Medina-Franco; Aminael Sánchez-Rodríguez; Fernanda Borges
Journal:  Drug Discov Today       Date:  2017-03-06       Impact factor: 7.851

Review 3.  Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?

Authors:  Lucio H Freitas-Junior; Eric Chatelain; Helena Andrade Kim; Jair L Siqueira-Neto
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-01-28       Impact factor: 4.077

Review 4.  Inhibition of microglia activation as a phenotypic assay in early drug discovery.

Authors:  Mariana Figuera-Losada; Camilo Rojas; Barbara S Slusher
Journal:  J Biomol Screen       Date:  2013-08-14

Review 5.  Advances in Development of New Treatment for Leishmaniasis.

Authors:  Juliana Perrone Bezerra de Menezes; Carlos Eduardo Sampaio Guedes; Antônio Luis de Oliveira Almeida Petersen; Deborah Bittencourt Mothé Fraga; Patrícia Sampaio Tavares Veras
Journal:  Biomed Res Int       Date:  2015-05-11       Impact factor: 3.411

6.  Integrated analysis identifies interaction patterns between small molecules and pathways.

Authors:  Yan Li; Weiguo Li; Xin Chen; Hong Jiang; Jiatong Sun; Huan Chen; Sali Lv
Journal:  Biomed Res Int       Date:  2014-07-13       Impact factor: 3.411

Review 7.  Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments.

Authors:  Patrik Brundin; Roger A Barker; P Jeffrey Conn; Ted M Dawson; Karl Kieburtz; Andrew J Lees; Michael A Schwarzschild; Caroline M Tanner; Tom Isaacs; Joy Duffen; Helen Matthews; Richard K H Wyse
Journal:  J Parkinsons Dis       Date:  2013-01-01       Impact factor: 5.568

Review 8.  The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery.

Authors:  Natalia V Segatto; Mariana H Remião; Kyle M Schachtschneider; Fabiana K Seixas; Lawrence B Schook; Tiago Collares
Journal:  Front Pharmacol       Date:  2017-12-05       Impact factor: 5.810

9.  Robustness and plasticity of metabolic pathway flux among uropathogenic isolates of Pseudomonas aeruginosa.

Authors:  Antje Berger; Katrin Dohnt; Petra Tielen; Dieter Jahn; Judith Becker; Christoph Wittmann
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

10.  Serotonin biosynthesis as a predictive marker of serotonin pharmacodynamics and disease-induced dysregulation.

Authors:  Richard W D Welford; Magali Vercauteren; Annette Trébaul; Christophe Cattaneo; Doriane Eckert; Marco Garzotti; Patrick Sieber; Jérôme Segrestaa; Rolf Studer; Peter M A Groenen; Oliver Nayler
Journal:  Sci Rep       Date:  2016-07-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.